Patents Assigned to Cardurion Pharmaceuticals, Inc.
  • PDE9 inhibitors for treating sickle cell disease
    Patent number: 12213975
    Abstract: The present disclosure relates to PDE9 inhibitors, pharmaceutical compositions comprising the PDE9 inhibitors, and methods of using the PDE9 pharmaceutical compositions for the treatment of sickle cell disease (SCD).
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: February 4, 2025
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Edward George Calamai, Deborah Lynn Leithead Dobbins, Michael Paul Dehart, James McArthur, Shi Yin Foo
  • Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
    Patent number: 12006319
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 11, 2024
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Suzanne Buttar, Mateusz Pitak, Adam Ross Patterson, Samuel Alexander Stratford, Ioana Sovago, Jun Xu, Peng Zhou, Haojuan Wei, Kuangchu Dai
  • Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
    Patent number: 11999741
    Abstract: The present disclosure relates to processes for preparing 64(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: June 4, 2024
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Niels Svenstrup, Jun Zhang, Jikui Sun, Yuyin Chen, Jianshe Kong, Rujian Ma, Junhua Zhang, Liang Qin, Huanming Xiao, Jinxu Sun, Xiao Meng, Fenglai Sun, Jingyang Zhu
  • Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
    Patent number: 11795172
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: October 24, 2023
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Nobuyuki Matsunaga, Junya Shirai, Tomohiro Okawa, Yasufumi Miyamoto, Zenyu Shiokawa, Takashi Nakahata, Akito Shibuya, Akira Kawada, Malcolm MacCoss